27 March 2013
London, Manchester, Munich, Boston, Sydney, Melbourne: Earlier this month College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.
Read more »